CD38 and Miyoshi myopathy: MOR202, a humanized CD38 antibody developed by Morphosys, is being studied as a monotherapy and combined with lenalidomide/dexamethasone or pomalidomide/dexamethasone in phase I/II trials for the treatment of refractory or relapsed MM.